Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Resolution of autoimmune thrombocytopenia associated with raltegravir use in an HIV-positive patient.

Gentile I, Bonadies G, Buonomo AR, Minei G, Borrelli F, Foggia M, Chiurazzi F, Borgia G.

Platelets. 2013;24(7):574-7. doi: 10.3109/09537104.2012.735721. Epub 2012 Nov 6.

PMID:
23130846
2.

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguyen BY; Protocol 005 Team.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):456-63.

PMID:
20306554
3.
4.

Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.

Monteiro P, Perez I, Pich J, Gatell JM, Martínez E.

J Antimicrob Chemother. 2013 Feb;68(2):404-8. doi: 10.1093/jac/dks416. Epub 2012 Oct 28.

PMID:
23109185
5.

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.

Macías J, Neukam K, Portilla J, Iribarren JA, de Los Santos I, Rivero A, Márquez M, Delgado M, Téllez F, Merino D, Giner L, von Wichmann MA, Pineda JA; HEPRAL study team.

J Antimicrob Chemother. 2011 Jun;66(6):1346-50. doi: 10.1093/jac/dkr083. Epub 2011 Mar 10.

PMID:
21398295
6.

Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):135-7.

PMID:
19480091
7.

Raltegravir-based regimens are effective in HIV-1 group O-infected patients.

Depatureaux A, Leoz M, Le Moal G, Pathé JP, Pavie J, Batisse D, Daneluzzi V, Genet P, Gerard L, Lascaux-Cametz AS, Lambolez T, Chennebault JM, Plantier JC.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):e1-3. No abstract available.

PMID:
22918125
8.

Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.

Nozza S, Galli L, Bigoloni A, Nicola G, Pogliaghi M, Cossarini F, Salpietro S, Galli A, Della Torre L, Tambussi G, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):e113-5. doi: 10.1097/QAI.0b013e31820a9ae4. No abstract available.

PMID:
21350358
9.

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.

Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.

AIDS. 2012 Jan 14;26(2):167-74. doi: 10.1097/QAD.0b013e32834e8955.

PMID:
22089379
10.

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B.

Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.

PMID:
22290239
11.

Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.

Briz V, León-Leal JA, Palladino C, Moreno-Perez D, de Ory SJ, De José MI, González-Tomé MI, Martín CG, Pocheville I, Ramos JT, Leal M, Muñoz-Fernández MÁ.

Pediatr Infect Dis J. 2012 Mar;31(3):273-7. doi: 10.1097/INF.0b013e31824580e8.

PMID:
22330165
12.

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group.

Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6.

PMID:
20371753
13.

Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.

Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A.

Haemophilia. 2012 Jan;18(1):108-11. doi: 10.1111/j.1365-2516.2011.02610.x. Epub 2011 Jul 18.

PMID:
21762404
14.

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group.

Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674.

PMID:
19757993
15.

Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.

Madeddu G, Menzaghi B, Ricci E, Carenzi L, Martinelli C, di Biagio A, Parruti G, Orofino G, Mura MS, Bonfanti P; C.I.S.A.I Group.

AIDS. 2012 Nov 28;26(18):2412-5. doi: 10.1097/QAD.0b013e32835aa141.

PMID:
23032413
16.

[Long-term therapy strategy with raltegravir. Appropriate in all illness phases].

Warpakowski A.

MMW Fortschr Med. 2011 May 5;153(18):50-1. German. No abstract available.

PMID:
21604599
17.

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.

Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M.

Clin Microbiol Infect. 2011 Jun;17(6):928-34. doi: 10.1111/j.1469-0691.2010.03375.x. Epub 2010 Nov 5.

18.

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.

PMID:
19648823
19.

Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

Do VT, Higginson RT, Fulco PP.

Am J Health Syst Pharm. 2011 Nov 1;68(21):2049-54. doi: 10.2146/ajhp110083.

PMID:
22011983
20.

Raltegravir-induced DRESS syndrome.

Loulergue P, Mir O.

Scand J Infect Dis. 2012 Oct;44(10):802-3. Epub 2012 Jul 17.

PMID:
22803794

Supplemental Content

Support Center